Abstract
This brand new report examines the forthcoming prospects for respiratory drugs
over the next 5 year. With in-depth sales forecasts for leading pharmaceutical
products, the report has been produced to inform you of future developments
and strategies. The respiratory market generated revenues of $30503m in 2006,
but what will it be in 2013,? Which year will see it reach its peak? This
report tells you.
The respiratory market contained ten blockbuster drugs in 2006, with the top
three being; Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that
there will be room for more blockbusters as the current products lose patent
protection. This detailed report also highlights pipeline developments and
important contemporary issues, especially commercial drivers and restraints.
The prevalence of respiratory diseases such as asthma, in the leading
pharmaceutical markets, has increased significantly over the past few decades.
Although there is some evidence to suggest that the rate of increase is
slowing, we believe that the prevalence will continue to increase and be a key
driver of this market throughout the forecast period of the report.
Sources include primary interviews and analysis unavailable elsewhere,
in-house industry databases, commercial news, published reports, economic
research and consultation with experts. Visiongain applies financial
forecasting, qualitative analyses and the assessment of unmet needs to provide
a comprehensive market report with detailed analysis and informed opinion.
In particular, The Respiratory Market concentrates on the following essential
aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2008-2013
- Drivers and restraints facing the respiratory market
- Opportunities and threats facing the respiratory market
- Growth of the respiratory drugs market between 2008-2013
- Commercial prospects for the market-leading drugs, with sales forecasts
from 2008-2013
- Individual forecasts of the leading drug classes from 2008-2013
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for respiratory drugs
from 2008-2013
- To discover predicted revenues, growth rates and other key metrics for
leading pharmaceutical treatments from 2008-2013
- To determine key activities of leading companies
- To discover "hot" pipeline developments and up-and-coming products
- To determine the forces that influence the market for respiratory products:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the market is heading - both technologically and
commercially
Do you know what the market values of these major therapeutic areas of the
respiratory market are?
The report provides in-depth market analysis upon these areas, and extensively
identifies both prescription and OTC respiratory drugs by product type. The
study also assess' the challenges faced by respiratory companies, and what
exciting market opportunities exist in this up- and-coming therapeutic area.
Why You Must Buy This Report?
This report features over 40 figures & graphs, 15 tables and charts, news,
insights, the latest developments and an in depth survey of the respiratory
market with up-to-date analysis. This report is a vital addition to gaining an
understanding of this highly profitable market sector and will give your
company ' the edge' on your competitors. You can not afford to be without this
latest report from visiongain.
| 
View Cart
